Background: Primary infliximab treatment failure is common in patients with inflammatory bowel disease and represents a challenge to clinicians.
A nti-tumor necrosis factor (TNF)-alpha therapy is effective for induction and maintenance of remission in patients with inflammatory bowel disease (IBD). [1] [2] [3] [4] [5] [6] Unfortunately, up to 40% of patients with IBD starting on an anti-TNF treatment have no clinical response to standard induction treatment and are thus classified as primary anti-TNF nonresponders. [7] [8] [9] Although not yet well characterized, primary anti-TNF treatment failure is believed to originate from pharmacokinetic or pharmacodynamic problems or both. The first issue has been ascribed to high inflammatory activity with an excessive TNFalpha load, fecal loss of the anti-TNF, 10, 11 and/or antibodies against the anti-TNF agent, [12] [13] [14] [15] although immunization seems less likely during the induction phase. [16] [17] [18] [19] [20] [21] The latter issue may be due to predominance of a non-TNF-alpha-driven immunoinflammatory disease mechanism. 15, 22 It is not yet possible to identify and stratify patients according to their risk of primary anti-TNF failure before initiation of therapy. 23 There is no current international consensus on how to handle IBD patients with primary anti-TNF treatment failure. 1, 7, 9, [17] [18] [19] [24] [25] [26] [27] [28] [29] These patients constitute a common challenge to clinicians, yet little is known about the prognosis after primary anti-TNF treatment failure. 1, 9 In a recent retrospective study, risk of colectomy was shown to be high in ulcerative colitis patients with primary treatment failure on infliximab. More than half (55.6%) of the patients had a colectomy within a median of 3.2 years after primary infliximab failure. 30 Also in Crohn's disease, primary infliximab treatment failure has been associated with a substantial increase in major abdominal surgery rate. 31 In addition, patients with primary treatment failure to infliximab often fail to respond to a second-line biologic drug leading to prolonged disease activity. 2, 3, 8, [32] [33] [34] [35] [36] Unfortunately, most randomized controlled trials of efficacy and safety of anti-TNF treatment have either excluded patients with primary anti-TNF failure or do not provide separate results for patients with former primary anti-TNF failure. 7, 21 With the new and upcoming treatment options for patients with IBD (including the possibility to switch out of class), it has become important to describe the prognosis of patients with primary anti-TNF failure. Therefore, we aimed to extend the available limited data in a large single-center cohort by assessing the prognosis, defined as surgery-free survival, in patients with primary infliximab treatment failure as compared to patients responding to infliximab induction therapy. Furthermore, we aimed to characterize medically interventions applied in patients with primary infliximab treatment failure, not handled by surgery, along with the corresponding outcomes.
MATERIALS AND METHODS

Study Design
This was a retrospective, observational, cohort study of all patients with Crohn's disease or ulcerative colitis treated with infliximab as first-line anti-TNF treatment at a tertiary Danish IBD center (Department of Gastroenterology, Copenhagen University Hospital at Herlev) from January 1, 2000 until December 31, 2015. Time to first IBD-related surgery was registered for all patients. For patients with primary infliximab treatment failure, the following were registered: patient and disease characteristics, including demographics, biochemistry, endoscopic and imaging findings, medications, and IBD-related surgery at specific time points (baseline, time of primary infliximab treatment failure, after 6 months, and after 12 months or end of follow-up). Diagnostic imaging techniques included magnetic resonance imaging (MRI), computed tomography, and transrectal ultrasonography (TRUS). Endoscopic procedures included colonoscopy and sigmoidoscopy. Clinical response to medical therapy applied after primary infliximab treatment failure was judged and classified by the authors as response or no response. This judgment was based on clinical assessments by treating senior gastroenterologists' noted in patient's medical records, biochemical findings, diagnostic imaging findings, and results from endoscopic procedures. The study was approved by the Danish Data Protection Agency (HEH-2015-028) and The Regional Ethics Committee of Region Hovedstaden, Denmark (H-15005685).
Definitions
Primary infliximab treatment failure was defined as no clinical effect based on treating physician's global assessment as noted in the patient medical records leading to discontinuation of infliximab after a minimum of 2 induction infusions or, in case of extensive ulcerative colitis, no effect of 1 rescue treatment followed by colectomy. Patients who discontinued infliximab because of side effects/complications or compliance issues were not included. The following were considered as IBD-related surgery (or interventions): bowel resection, diverting ileostomy, surgical strictureplasty, endoscopic balloon dilation, fistulotomy and fistolectomy. Incision of abscess and simple fistula drainage (seton) were not included, neither were non-IBD-related surgeries (e.g., hernia repair, cholecystectomy, and cancer surgery). Response to medical therapy applied after primary infliximab treatment failure was defined as: Clear clinical improvement with an obvious decrease in disease activity (symptoms and/or clinical findings) and continuation of the medical therapy. No response to medical therapies applied after primary infliximab treatment failure was defined as: Active disease with no improvement of symptoms and clinical findings.
Statistical Analyses
Descriptive statistics were stated as frequencies and percentages for discrete variables, and medians with interquartile ranges for continuous variables. Categorical data were analyzed using Fisher's exact test. The Wilcoxon test was used to compare nonparametric paired data. Kaplan-Meier statistics were used for survival analyses, and log-rank test for comparison of survival curves. Data were analyzed in IBM SPSS 23.0 (Mac) or GraphPad Prism version 7 (Mac). Two-sided P-values ,0.05 were considered statistically significant.
RESULTS
Study Population
A total of 560 patients with IBD (Crohn's disease n ¼ 353 and ulcerative colitis n ¼ 207) received treatment with infliximab as the primary anti-TNF agent (Fig. 1 ). Among these, 81 (15%) had primary infliximab treatment failure (33 [9%] patients with Crohn's disease and 48 [23%] with ulcerative colitis) after a median of 3 infliximab infusions (interquartile range 2-4) (Fig. 1) . The remaining 479 patients had response to infliximab induction.
Patient Characteristics
Characteristics of patients with primary infliximab treatment failure are listed in Table 1 . Nearly two-thirds of patients with Crohn's disease were treated with infliximab primarily because of luminal disease activity (n ¼ 20, 61%). Among patients with ulcerative colitis, indications for infliximab were pancolitis (54%), left-sided colitis (33%), and proctitis (13%). All patients had verified disease activity assessed by endoscopy, capsule endoscopy, MRI, and/or TRUS before initiation of infliximab. All patients were initially treated with infliximab 5 mg/kg. The majority of patients (n ¼ 50, 62%) completed standard induction with infliximab (5 mg/kg at weeks 0, 2, and 6). Eight patients (10%) received an intensified induction regimen with infliximab. 
Surgery as Immediate Approach After Primary Infliximab Treatment Failure
The immediate approach after primary infliximab treatment failure was surgery in 60% (n ¼ 29) of patients with ulcerative colitis and in 33% (n ¼ 11) of patients with Crohn's disease. The risk of surgery as immediate approach was significantly higher in patients with ulcerative colitis than in patients with Crohn's disease (odds ratio 3.1 [1.2-7.7], P ¼ 0.02) (Fig. 1) .
Surgery-free Survival After Primary Infliximab Treatment Failure
In IBD patients with primary infliximab treatment failure, the median surgery-free survival was 196 days after the first infliximab infusion (ulcerative colitis median 141 days versus Crohn's disease median 260 days) (Fig. 2) . There was no significant difference in surgery-free survival between the percentage of patients with primary infliximab treatment failure with ulcerative colitis and Crohn's disease (P ¼ 0.79) (Fig. 2) . Patients with primary infliximab treatment failure receiving #2 infliximab infusions had a significantly shorter time to surgery (median surgery-free survival of 54 days) as compared to patients receiving full induction therapy (293 days) (Fig. 3) .
Surgery in Patients with Primary Infliximab Failure Versus Initial Responders
Compared with initial responders, patients with primary infliximab treatment failure faced an overall significantly higher risk of IBD-related surgery: odds ratio 6.3 (3.8-10.6), (P , 0.0001). After 1 year, the majority of patients with primary infliximab treatment failure (n ¼ 51, 63%) had undergone IBD-related surgery (Crohn's disease n ¼ 19 [58%], ulcerative colitis n ¼ 32 [67%]; P ¼ 0.49). By contrast, a total of 25% (120 of 479) of patients with initial response to infliximab therapy needed IBD-related surgery during the entire follow-up period. Interestingly, among patients with initial response to infliximab therapy, the rate of surgery was significantly lower for patients with ulcerative colitis than for patients with Crohn's disease (P , 0.01) (Fig. 2) . This is in contrast to what was observed in the failure group.
Nonsurgical Approach Immediately After Primary Infliximab Treatment Failure and Outcomes
Patients who did not undergo surgery as immediate action after primary infliximab treatment failure (n ¼ 41) (Fig. 1) were as first approach treated with initiation or optimization of conventional immunosuppressive agents (n ¼ 13, 32%), topical treatment (n ¼ 10, 24%), systemic steroids (n ¼ 9, 22%), a second anti-TNF (n ¼ 11, 27%), and/or a cell migration inhibitor (n ¼ 2, 5%). Medical treatments applied as first approach after primary infliximab treatment failure and corresponding outcomes are detailed in Figure 4 . After first medical treatment approach, 63% (n ¼ 26) still had active IBD.
Nonsurgical Approach Within First Year After Primary Infliximab Treatment Failure and Outcomes
During the entire first year after primary infliximab treatment failure, patients who were not treated surgically (n ¼ 30, 37%) were treated with initiation or optimization of conventional immunosuppressive agents (n ¼ 18, 60%), topical treatment (n ¼ 12, 40%), systemic steroids (n ¼ 9, 30%), a second anti-TNF (n ¼ 8, 27%), and/or a cell migration inhibitor (n ¼ 4, 13%) (Fig. 5) .
Among patients treated medically during the first year after primary infliximab treatment failure, 16 (53%) (Crohn's disease n ¼ 10 and ulcerative colitis n ¼ 6) still had active disease after 1 year (Fig. 5) . Of these 16 patients, 14 (88%) had the continued 
DISCUSSION
This study reports data on primary infliximab treatment failure from a large cohort of patients with IBD treated at a single tertiary referral center. We found that 15% of IBD patients treated with infliximab experienced no response to induction therapy (primary failure). Compared with patients experiencing initial response, patients with primary treatment failure to infliximab had a poor prognosis with significantly increased risk of IBD-related surgery and suboptimal response to subsequent medical treatment.
The risk of primary failure to infliximab in IBD reported in this study is in agreement with the findings in other observational studies. 7, 9, 37 Higher rates of primary treatment failure to infliximab have been reported in prospective, randomized clinical trials presumably due to the inclusion and exclusion criteria and to more stringent definitions of response (and thus more liberal definitions of nonresponse). In our cohort, almost half of patients with ulcerative colitis who failed in infliximab treatment had either proctitis or left-sided colitis. This observation is similar to findings in another cohort of patients with primary infliximab nonresponders 30 and may reflect the nature of the disease.
Although surgery may be necessary in the treatment of IBD, the overall goal is essentially intestinal sparing, and in that perspective, our findings clearly show a poor prognosis after primary infliximab treatment failure. Accordingly, Papamichael et al 30 recently showed that more than half (55.6%) of patients with ulcerative colitis with primary infliximab failure underwent colectomy within few years. Likewise in Crohn's disease, primary infliximab treatment failure led to an increase in abdominal surgery rate. 31 Patients in our cohort were all treated by the conventional step-up strategy, and many of the patients had extensive disease at the time of introduction of infliximab. This may have had an effect both on the risk of primary infliximab treatment failure and the timing of introduction of surgery.
This group of patients with initial response to infliximab treatment included a wide range of different response types: some patients experienced maintained clinical response (partial remission and complete remission), whereas others had secondary loss of response, an allergic reaction (early or late), and/or compliance problems. Despite the variation in the group of patients with initial response, we showed a significantly lower risk of surgery compared with patients with primary infliximab treatment failure. Based on the present data, we cannot attribute the entire beneficial outcome to infliximab. Nevertheless, our results are in line with previous studies showing that anti-TNF treatment has the capacity to reduce the risk of surgery and to induce and maintain remission. 1, 5, 21, 38, 39 In addition, we found that in patients with initial response to infliximab, the rate of surgery was significantly lower for patients with ulcerative colitis, compared with patients with Crohn's disease.
Medical treatment of patients with primary failure to anti-TNF is clinically challenging because these patients typically already have failed on or been intolerant of conventional treatment. Guidelines are not clear on how patients with primary anti-TNF failure should be treated. 1, 7, 9, [17] [18] [19] [23] [24] [25] [26] [27] [28] In patients with severe ulcerative colitis, it is increasingly recognized that these patients should be treated early with higher or frequent dosages probably because of increased drug consumption (antigen sink) and fecal loss (due to increased intestinal leakage secondary to inflammation). As in patients with secondary anti-TNF treatment failure, it has been proposed that measurements of serum levels of infliximab and anti-infliximab antibodies can be used to guide interventions in patients with primary anti-TNF treatment failure. 7, 15 However, prospective studies demonstrating the usefulness of this approach are lacking. The earlier mentioned uncertainty about how to handle primary infliximab treatment failure is reflected in our cohort in which patients with primary infliximab treatment failure were treated with a broad range of medical therapies. Despite this intensive medical treatment, half of the patients continued to have active disease after 1 year. Unfortunately, because of the limited number of patients and the nonrandomized design, a formal comparison between types of medical approach and response was not possible. Switching to a second-line anti-TNF agent, as opposed to second-line non-anti-TNF treatment, is controversial. 29 Patients with primary infliximab treatment failure often fail to respond to the second-line drug as well. 2, 3, 8, 30, [32] [33] [34] 40 In a recent meta-analysis, 30% of Crohn's disease patients with primary anti-TNF treatment failure obtained remission after switching to another anti-TNF. 8 Recent results from Papamichael et al 30 showed that patients switching to a second anti-TNF agent had higher 3. Time to surgery in IBD patients with primary infliximab treatment failure receiving #2 infliximab infusions or full infliximab induction therapy. Full infliximab induction therapy was minimum three infliximab infusions given as induction therapy (e.g., week 0, 2, and 6).
probability for cumulative nonresponse compared with those switching to non-TNF-alpha inhibiting biological therapies. A randomized, controlled clinical efficacy trial has shown that vedolizumab induces remission in 26% of patients with previous anti-TNF failure. 40 However, it is not clear how many of the patients included were true primary nonresponders and how the effect was in these specific patients. Head-to-head studies evaluating how to treat patients after primary treatment failure of an anti-TNF agent are not available. Our study is based on data mainly gathered before the routine clinical introduction of non-TNF-alpha-inhibiting biological therapies (e.g., vedolizumab). Therefore, it has not been possible to evaluate the effect of these drugs on the outcome of patients with primary infliximab treatment failure.
The limitations of the study include the retrospective setup and the fact that disease activity was not evaluated by a validated clinical score. In the few patients (n ¼ 8), in whom primary infliximab treatment failure was not objectively verified (by endoscopy, MRI, TRUS, or examination of an intestinal bowel resection specimen), symptoms could to some extent be caused by noninflammatory disease (e.g., irritable bowel syndrome) superimposed on controlled IBD, although the clinical data make this less likely. Furthermore, we cannot exclude that some patients (e.g., with an element of both inflammatory and fibrotic stenosis) could have benefited from surgery to begin with instead of trying infliximab first. Another limitation was that the large group of patients classified as initial responders to infliximab were not clinically characterized in the same way as patients with primary infliximab treatment failure regarding extend/severity of disease, previous surgeries, concomitant therapies, biochemical parameters etc., and therefore, comparisons should be made with caution. However, our results are real-life data obtained from a large cohort with a long follow-up and from series of consecutive data from patients with primary infliximab treatment failure.
In conclusion, patients with IBD who experience primary infliximab treatment failure have a very poor prognosis. Hence, most patients require IBD-related surgery within 1 year. Among those who avoid surgery, approximately half have ongoing inflammatory active disease at 1 year. The finding of our study demonstrates that patients with primary infliximab treatment failure have an unmet therapeutic need. There is a need for new treatment strategies with early intensified infliximab in some patients and non-TNF-alpha inhibitor treatment in others.
